IDEAYA Biosciences (IDYA) Cash from Operations (2018 - 2026)
IDEAYA Biosciences (IDYA) reported Cash from Operations of 75170000.0 for Q1 2026, down 24.57% on a YoY basis from 99659624.29 in Q1 2025, and up 16.94% sequentially from 90496000.0 in Q4 2025.
IDEAYA Biosciences (IDYA) Cash from Operations (2018 - 2026) Analysis & Trends
IDEAYA Biosciences (IDYA) has 9 years of Cash from Operations data on file, last reported at 75170000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 24.57% year-over-year to 75170000.0; the trailing twelve-month figure through Mar 2026 stood at 85926000.0 (up 67.47% YoY), and the FY2025 full-year result was 71098000.0, up 71.28% from the prior year.
- Cash from Operations improved to 75170000.0 in Q1 2026, from 90496000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 142214000.0 in Q3 2025 to a low of 121655000.0 in Q4 2024.
- A 5-year average of 35073588.24 and a median of 32882000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 412.27% in 2024 and jumped 388.85% in 2025, its largest moves.
- Tracing IDYA's Cash from Operations over 5 years: stood at 23370000.0 in 2022, then retreated by 1.62% to 23748000.0 in 2023, then sank by 412.27% to 121655000.0 in 2024, then rose by 25.61% to 90496000.0 in 2025, then rose by 16.94% to 75170000.0 in 2026.
- Business Quant data shows IDYA's Cash from Operations at 75170000.0 in Q1 2026, 90496000.0 in Q4 2025, and 142214000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | IDEAYA Biosciences | 3.21 Bn | 2.54 Bn | - | -75.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.17 Mn |
| Mar 31, 2026 | -75.17 Mn |
| Dec 31, 2025 | -90.50 Mn |
| Dec 31, 2025 | -90.50 Mn |
| Sep 30, 2025 | 142.21 Mn |
| Sep 30, 2025 | 142.21 Mn |
| Jun 30, 2025 | -62.47 Mn |
| Jun 30, 2025 | -62.47 Mn |
| Mar 31, 2025 | -60.34 Mn |
| Mar 31, 2025 | -60.34 Mn |
| Dec 31, 2024 | -121.66 Mn |
| Dec 31, 2024 | -121.66 Mn |
| Sep 30, 2024 | -49.23 Mn |
| Sep 30, 2024 | -49.23 Mn |
| Jun 30, 2024 | -32.88 Mn |
| Jun 30, 2024 | -32.88 Mn |
| Mar 31, 2024 | -43.81 Mn |
| Mar 31, 2024 | -43.81 Mn |
| Dec 31, 2023 | -23.75 Mn |
| Dec 31, 2023 | -23.75 Mn |